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I
n patients presenting with an acute coronary syndrome (ACS), which includes unstable angina and non-ST-segment elevation myocardial infarction, randomized clinical trials have shown that the addition of IV unfractionated heparin to aspirin therapy is associated with a 50% reduction in the risk of myocardial infarction and death. 1 In recent years, low-molecular-weight heparin (LMWH) therapy has been found to be as effective, [2] [3] [4] or more effective [5] [6] [7] than IV unfractionated heparin for the initial treatment of patients with an ACS, and has not been associated with an increased risk of bleeding complications. From a practical standpoint, LMWH therapy is appealing because, unlike unfractionated heparin, it can be administered subcutaneously, with a fixed, weight-based dose, and without the need for laboratory monitoring. 8, 9 Based on these considerations, LMWH therapy is recommended by consensus groups for the initial treatment of patients with an ACS. 10, 11 In many clinical centers, enoxaparin is the LMWH of choice for the treatment of an ACS, and has supplanted unfractionated heparin therapy for this clinical indication.
However, the randomized controlled trials that investigated enoxaparin and other LMWHs in patients with an ACS have limitations in addressing practical issues that may impact on the bleeding risk of patients assessed in "real-world" clinical practice. First, patients with renal insufficiency, in whom there is the potential for bioaccumulation of LMWH, 8 were excluded from these clinical trials, as were patients weighing Ͼ 100 kg in whom there are scant data as to the safety of weight-based LMWH dosing. 12, 13 Second, the bleeding risks associated with enoxaparin therapy were not addressed in the context of coadministered aspirin and clopidogrel therapy, which are frequently used for the initial treatment of an ACS. 10, 11 Furthermore, co-administration of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), was also not addressed in previous studies. Third, these randomized trials enrolled selected patients who were at low risk for bleeding complications, 14 and LWMH was administered in a closely monitored clinical setting. Consequently, the incidence of bleeding complications in these studies may not be representative of the bleeding risks in a real-world clinical setting. We, therefore, performed a 1-year audit of clinical practice relating to the administration of enoxaparin for the initial treatment of patients with an ACS. The objectives of this study were as follows: (1) to describe real-world enoxaparin dosing practices, and (2) to identify risk factors for bleeding complications in this clinical setting.
Materials and Methods

Patients
We performed a chart review of consecutive patients who were discharged between September 1, 2000, and September 1, 2001 , from the Coronary Care Unit of St. Joseph's Hospital, Hamilton, a tertiary-care, university-affiliated, teaching hospital without a cardiac catheterization laboratory. Patients with a discharge diagnosis of unstable angina or myocardial infarction were identified using the MacTRAC (Telosa Software; Palo Alto, CA) database system, which electronically records all patient discharge information. At this hospital, enoxaparin is the LMWH of choice for the initial treatment of patients with an ACS, and the pharmacy-recommended dosing is enoxaparin, 1 mg/kg bid. In patients weighing Ͼ 100 kg, the dose is capped so that the maximal administered dose is 100 mg bid.
To be to be eligible for this chart review, patients had to satisfy prespecified criteria so that the study population was homogeneous in terms of a diagnosis of an ACS, and received a standardized antithrombotic regimen that involved enoxaparin, 1 mg/kg bid. In this way, we would minimize potential co-interventions that might influence the determinants of bleeding, and the study findings would be generalizable to a prespecified patient group. Thus, patients included in the analysis had to satisfy the following inclusion criteria: (1) age Ͼ 18 years; (2) discharge diagnosis of unstable angina or non-ST-segment elevation myocardial infarction, defined by chest pain of Ͼ 30 min duration or increased frequency of angina at rest or with minimal exertion in the previous 12 h, and new ST-segment depression or T-wave inversion on electrocardiography or cardiac troponin-I Ͼ 0.5 mol/L; (3) received at least one dose of enoxaparin, 1 mg/kg, by subcutaneous injection. Patients were therefore excluded if they received an antithrombotic treatment that might bias an assessment of bleeding risks associated with the prespecified treatment of interest (ie, enoxaparin, 1 mg/kg bid): (1) IV unfractionated heparin, (2) thrombolytic agent; and (3) a LMWH dose or preparation other than the prespecified enoxparin regimen.
For patients with multiple hospital admissions during the surveillance period, only the first hospital admission was counted to minimize bias that may result from including patients on multiple occasions who might or might not have had a predisposition to bleeding. Patients who required a percutaneous coronary intervention or coronary bypass surgery were transferred to the regional cardiovascular center, and did not undergo further clinical follow-up after transfer out of the coronary care unit.
Outcomes
The following data were extracted from the patient medical records: (1) clinical characteristics and laboratory test results; (2) initial enoxaparin dose, changes in enoxaparin dose and reason for dose changes, and number of enoxaparin doses administered; and (3) bleeding events, defined a priori as major or minor. Major bleeds were episodes that were clinically overt and associated with one of the following outcomes: transfusion of Ն 2 U of packed RBCs; decrease in hemoglobin Ͼ 20 g/L within 24 h; retroperitoneal, intracranial or body cavity bleeding; or death. Minor bleeding was defined as any other bleeding episode, including enoxaparin injection site bruising and transient epistaxis or hematuria.
Potential Risk Factors for Bleeding
The following patient clinical and treatment characteristics were identified, a priori, as potential determinants of bleeding risk: (1) age; (2) sex; (3) body weight; (4) serum creatinine; (5) creatinine clearance, calculated based on the Cockroft-Gault formula; 15 (6) number of enoxaparin doses received; (7) coadministered aspirin, clopidogrel, or NSAIDs; and (8) previous peptic ulcer disease.
Statistical Analysis
The proportion and clinical characteristics of patients who had body weight documentation and received a weight-based dose of enoxaparin was described. Univariable and multivariable logistic regression analysis was used to identify independent predictors of bleeding. The odds ratio (OR) and corresponding 95% confidence interval (CI) was reported for each variable in the model. Variables were retained in the final multivariable model if their level of significance was Յ 0.10. Statistical significance was declared for a predictor variable at p Ͻ 0.05.
Results
Patients
In total, 487 charts of patients discharged from the coronary care unit were reviewed, of which 250
consisted of patients with an ACS. Of this group, 42 patients were excluded because they received IV unfractionated heparin (n ϭ 28), a thrombolytic agent (n ϭ 9), or a LMWH preparation other than enoxaparin (n ϭ 5), leaving 208 patients for this analysis. The clinical and laboratory characteristics of these patients are presented in Table 1 . Overall, approximately two thirds of patients had a non-STsegment elevation myocardial infarction, one third had unstable angina, and almost all of the patients (97%) received aspirin therapy. The duration of hospital stay was, on average, 10 days (range, 1 to 61 days), and patients received, on average, 9 doses (range, 1 to 50 doses) of enoxaparin. In terms of coadministered antiplatelet therapy, 201 patients (97%) received aspirin, 55 patients (26%) received clopidogrel, and 2 patients (1%) received ticlopidine.
Patients received antiplatelet therapy throughout the period of study unless a bleeding episode developed.
Enoxaparin Dosing Practices
The dosing practices for enoxaparin are presented in Table 2 . Overall, 19 patients (9%) did not have body weight documentation. Of 189 patients who had body weight documentation, 48 patients (23%) received an enoxaparin dose that was Ͼ 10% or Ͻ 10% the recommended 1 mg/kg dose; 27 patients (13%) received the maximum, 100 mg bid, enoxaparin dose; and 17 patients (8%) had renal impairment with a serum creatinine Ͼ 150 mol/L. Of 96 patients who had body weight documentation and required an enoxaparin dose adjustment because the initial dose did not correspond to the recommended 1 mg/kg dose regimen, the dose was changed in 27 of these patients (28%).
Bleeding Events and Risk Factors For Bleeding
There were 35 bleeding events (17%), of which 8 events (4%) were major. The major bleeds included two retroperitoneal bleeds, two upper GI bleeds, one rectus abdominus hematoma, and three bleeding episodes associated with a decrease in hemoglobin and transfusion of Ն 2 U of packed RBCs. None of the bleeding events were fatal. Risk factors for any (major or minor) and major bleeding, based on the univariable analysis, are presented in Table 3 . In the multivariable analysis, risk factors for any bleeding, and major bleeding are presented in Table 4 and  Table 5 , respectively. Risk factors that were independently associated with an increased risk for any bleeding were increasing age, coadministered nonsteroidal anti-inflammatory or antiplatelet drug therapy, and number of enoxaparin doses administered. Risk factors that were independently associated with an increased risk for major bleeding were increasing age, and coadministered clopidogrel therapy. Two factors were associated with an increased risk for major bleeding, although these associations did not quite attain statistical significance: the number of enoxaparin doses administered (p ϭ 0.084), and increasing serum creatinine concentration (p ϭ 0.079). The use of angiotensin-converting enzyme inhibitors were associated with a significantly lower risk of any bleeding (p ϭ 0.25), although this association did not reach statistical significance with major bleeding (p ϭ 0.062).
Discussion
We assessed real-world dosing practices and identified risk factors for bleeding in 208 patients admitted to a coronary care unit and received enoxaparin for the initial treatment of an ACS. There are two conclusions that follow from our analysis. First, enoxaparin dosing practices were suboptimal. Approximately 1 in 5 patients received Ͼ 10% or Ͻ 10% of the recommended, 1 mg/kg, weight-based dose of enoxaparin; approximately 1 in 10 patients did not have body weight documentation to allow weight-based enoxaparin dosing; and approximately 1 in 12 patients had significant renal impairment, with a serum creatinine Ͼ 150 mol/L, in whom there was the potential for excessive accumulation of enoxaparin. Second, risk factors that were associated with an increased risk of bleeding were coadministered clopidogrel or NSAIDs, increasing patient age, and increasing serum creatinine.
There were missed opportunities for optimal enoxaparin administration that would incorporate weightbased dosing and dose adjustments, or alternative drug treatment with unfractionated heparin because of renal impairment. Observational studies 16, 17 have provided some insight as to the determinants of drug-related adverse events that could apply to LMWH for the treatment of patients with an ACS. Suggestions that may improve the safety of LMWH administration include standing orders for patient weight documentation, dose limits in patients weighing Ͼ 100 kg, and serum creatinine thresholds. In addition, documentation of risk factors for bleeding, including a previous history of bleeding, active peptic ulcer disease, thrombocytopenia, and coadministration of drugs affecting hemostasis, might heighten awareness of the bleeding risks associated with LMWH. Clinically important, or major, bleeding occurred in eight patients (4%), a rate that may be higher than that observed in structured clinical trials. There are two clinical trials involving patients with an ACS who received an enoxaparin dose regimen (ie, 1 mg/kg bid) and treatment duration (ie, 2 to 14 days) that was comparable to that of our study population. In these studies, 5,7 the incidence of major bleeding was lower than that in our study population, with an incidence of 1.5% (29 of 1,953 patients) and 1.9% (6 of 309 patients), respectively. Although a higher rate of major bleeding of 6.3% (102 of 1,607 patients) was reported in one clinical trial 6 of patients with an ACS who received the same enoxaparin dose regimen, most of these bleeds occurred during or after coronary artery bypass surgery and were not attributable to enoxaparin therapy administered for the initial treatment of an ACS, as in our study.
There were several clinical factors that appeared to influence the risk of bleeding in our study population. Coadministration of clopidogrel, which was received by 26% of patients, was the strongest predictor of bleeding. Such patients had an almost eightfold increased risk of major bleeding compared to patients who did not receive clopidogrel (OR, 7.70; 95% CI, 1.16 to 51.9). The use of NSAIDs or other antiplatelet drugs affecting hemostasis was also a predictor of bleeding, as such patients had approximately a twofold increased risk of any bleeding (OR, 2.38; 95% CI, 1.06 to 5.38). These findings are not surprising because coadministration of multiple drugs affecting hemostasis will increase the risk of bleeding. 18 -21 Increasing age was also associated with an increased risk for bleeding (OR, 1.57; 95% CI, 1.13 to 2.20). Increasing age as a potential risk factor for bleeding has not been addressed in clinical trials of LMWH in patients with an ACS. In studies investigating LMWH therapy in patients with venous thromboembolism, the findings are variable. One study 22 found that there was no increased risk of major bleeding in an elderly population, while a French survey 23 noted increased bleeding episodes in such patients. Elderly patients may have clinical factors associated with an increased risk for bleeding, such as generalized frailty, a tendency for falls, and occult peptic ulcer disease, 24, 25 but are not accounted for in assessments of bleeding risk factors. Another relevant issue is the potential for bioaccumulation of enoxaparin in patients with renal impairment because enoxaparin is cleared primarily by the kidney. 26 In our study, a creatinine clearance Ͻ 25 mL/min, which corresponds to significant renal impairment, occurred in 3% of all patients but in 25% of patients with major bleeding. In a retrospective cohort study 27 of 106 patients with an ACS who received enoxaparin, 1 mg/kg, patients with renal dysfunction had a higher risk of any bleeding (51% vs 22%, p Ͻ 0.001) and major bleeding (30% vs 2%, p Ͻ 0.001) than those with normal renal function. Furthermore, in a substudy of the Thrombolysis in Myocardial Infarction 11B trial 28 involving patients with an ACS who received enoxaparin, 1 mg/kg, the incidence of major bleeding was significantly higher in patients with renal dysfunction than those with normal renal function (7.5% vs 1.2%, p Ͻ 0.01). Some authorities have suggested that laboratory monitoring of the anticoagulant effect of LMWH therapy, with anti-factor Xa heparin measurements, might be warranted if LMWHs are administered to patients with significant renal insufficiency. 29 Our finding that use of angiotensin-converting enzyme inhibitor therapy appeared to decrease the risk of bleeding complications (OR, 0.25; 95% CI, 0.08 to 0.84) is difficult to explain, due to a lack of biological plausibility, and may be due to chance.
There are potential limitations of this study that should be addressed. First, we acknowledge that as a retrospective chart review, there may have been inadequate documentation of relevant data that could influence the validity of our results. However, our analysis was based on drug use, which requires specific documentation in the patient record, and objective clinical information, such as patient age and weight that is not subject to biased interpretation. Second, although the bleeding outcomes that we included were initially documented based on a subjective clinical assessment, we used prespecified standardized criteria to differentiate clinically important, or major, bleeding from other bleeding episodes that might have been preferentially documented in patients' medical record because of prior knowledge of LMWH therapy. Third, we did not assess if patients who required invasive cardiac procedures, such as coronary angiography or coronary revascularization, had an increased risk for bleeding since these procedures, if required, were undertaken at another institution. In one study 30 of patients with an ACS who, during treatment with enoxaparin, 1 mg/kg bid, or IV unfractionated heparin, required urgent coronary bypass surgery, there was a higher risk of postoperative bleeding in patients who received enoxaparin (7.9% vs 3.7%, p ϭ 0.03). However, in patients with an ACS who required a percutaneous coronary intervention, concurrent therapy with enoxaparin, 1 mg/kg bid, did not appear to increase the risk for bleeding complications when the intervention was undertaken within 8 h of the last subcutaneous dose of enoxaparin. 31 To summarize, our clinical practice assessment of enoxaparin therapy in patients with an ACS found that dosing practices were suboptimal, and might confer a higher-than-expected risk of clinically im-portant bleeding complications. Increasing patient age, and co-administration of clopidogrel and other drugs that affect hemostasis were major determinants of bleeding.
